New ESCMID/ERS guidelines for diagnosis and treatment of chronic pulmonary aspergillosis
Wednesday, July 18, 2018 - 13:13Slide presentation (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - July 18, 2018 Category: Respiratory Medicine Authors: BethBradshaw Source Type: news

Invasive aspergillosis in haematology New guidelines
Wednesday, July 18, 2018 - 13:10Slide presentation (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - July 18, 2018 Category: Respiratory Medicine Authors: BethBradshaw Source Type: news

Recent advances in allergic bronchopulmonary aspergillosis complicating asthma
Wednesday, July 18, 2018 - 13:05Slide presentation (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - July 18, 2018 Category: Respiratory Medicine Authors: BethBradshaw Source Type: news

Recent Advances in Allergic Bronchopulmonary Aspergillosis Complicating Cystic Fibrosis
Wednesday, July 18, 2018 - 13:02Slide presentation (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - July 18, 2018 Category: Respiratory Medicine Authors: BethBradshaw Source Type: news

Pulmatrix touts data from first-in-human trial of inhaled anti-fungal therapy
Pulmatrix (NSDQ:PULM) said today that all dosing and follow-up visits have finished for its first-in-human study of an inhaled formulation of itraconazole as a treatment of allergic bronchopulmonary aspergillosis in people with asthma. The inhaled iSperse formulation, called Pulmazole, was well-tolerated, according to the Lexington, Mass.-based company. Pulmatrix plans to launch a Phase II trial of its ABPA therapy in the fourth quarter this year. Get the full story at our sister site, Drug Delivery Business News. The post Pulmatrix touts data from first-in-human trial of inhaled anti-fungal therapy appeared first on ...
Source: Mass Device - July 17, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Pharmaceuticals Wall Street Beat Pulmatrix Inc. Source Type: news

Aspergillosis Trust
Post date: 3 Jul 2018 - 9:38am (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - July 3, 2018 Category: Respiratory Medicine Authors: GAtherton Source Type: news

Chronic Pulmonary Aspergillosis Network (CPAnet)
Mon, 07/02/2018 - 13:13News blog (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - July 2, 2018 Category: Respiratory Medicine Authors: GAtherton Source Type: news

Two point-of-care tests for invasive aspergillosis launched
Thu, 06/21/2018 - 16:05News blog (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - June 21, 2018 Category: Respiratory Medicine Authors: BethBradshaw Source Type: news

Comment on "Sterilizing immunity in the lung relies on targeting fungal apoptosis-like programmed cell death"
Shlezinger et al. (Reports, 8 September 2017, p. 1037) report that the common fungus Aspergillus fumigatus, a cause of aspergillosis, undergoes caspase-dependent apoptosis-like cell death triggered by lung neutrophils. However, the technologies they used do not provide reliable evidence that fungal cells die via a protease signaling cascade thwarted by a fungal caspase inhibitor homologous to human survivin. (Source: ScienceNOW)
Source: ScienceNOW - June 21, 2018 Category: Science Authors: Aouacheria, A., Cunningham, K. W., Hardwick, J. M., Palkova, Z., Powers, T., Severin, F. F., Vachova, L. Tags: Immunology, Microbiology t-comment Source Type: news

Consultant in Infectious Diseases (National Aspergillosis Centre, UK)
(Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - June 15, 2018 Category: Respiratory Medicine Authors: GAtherton Source Type: news

Clinical Fellow - Infectious Diseases and Aspergillosis
(Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - June 4, 2018 Category: Respiratory Medicine Authors: BethBradshaw Source Type: news

Clinical Fellow – Infectious Disease and National Aspergillosis Centre
(Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - May 29, 2018 Category: Respiratory Medicine Authors: ROrritt Source Type: news

What Causes Hyponatremia?
Discussion Normal kidneys regulate water balance to maintain a plasma osmolality of 275-290 mOsm/kg normally. Thirst and arginine vasopressin or antidiuretic hormone (ADH) are the primary regulators of plasma osmolality. ADH is made in the hypothalamus and released by the posterior pituitary gland. ADH acts on the kidney’s distal collecting duct to increase water reabsorption. ADH is appropriately released in hypovolemic states, such as dehydration caused by gastroenteritis. ADH has an ~10 minute half-life and therefore can respond to rapid changes in volume status. Sodium balance is regulated by aldosterone (as part...
Source: PediatricEducation.org - April 23, 2018 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news

Severe fever with thrombocytopenia syndrome complicated by invasive aspergillosis
Tue, 03/27/2018 - 14:06News blog (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - March 27, 2018 Category: Respiratory Medicine Authors: ROrritt Source Type: news

Latest ESCMID-ECMM-ERS Clinical Guidelines for Aspergillosis Published
Mon, 03/26/2018 - 15:51News blog (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - March 26, 2018 Category: Respiratory Medicine Authors: GAtherton Source Type: news

Lessons to be learned from an invasive aspergillosis outbreak in a Japanese haematology ward
Thu, 03/22/2018 - 13:42News blog (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - March 22, 2018 Category: Respiratory Medicine Authors: BethBradshaw Source Type: news

8th Advances Against Aspergillosis, Lisbon, Portugal
 8th Advances Against Aspergillosis took place 1-3rd February 2018 in the pleasant sunshine of Lisbon, Portugal, leaving the snow of Manchester 2016 far behind. This is the only conference focussing on this fungal disease and has been running since 2004, attracting 400 researchers from all over the world  and since 2012 has also been holding a parallel meeting for patients with aspergillosis and their carers.Post date: 7 Mar 2018 - 3:16pm (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - March 7, 2018 Category: Respiratory Medicine Authors: GAtherton Source Type: news

Single Aspergillus fumigatus inoculation induces aspergillosis in falcons
Thu, 02/22/2018 - 10:29News blog (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - February 22, 2018 Category: Respiratory Medicine Authors: ROrritt Source Type: news

Why does ibrutinib carry a risk of cerebral aspergillosis?
Wednesday, February 21, 2018 - 14:33Slide presentation (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - February 21, 2018 Category: Respiratory Medicine Authors: ROrritt Source Type: news

How to get rid of black mould and damp: Avoid catching aspergillus with these five steps
BLACK mould and damp is a common problem during this time of year and respiratory problems, allergies, and asthma can be a result of infestations. Inhaling tiny bits of mould can also cause a condition called aspergillosis. The NHS explains how best to get rid of mould and damp problems. (Source: Daily Express - Health)
Source: Daily Express - Health - February 19, 2018 Category: Consumer Health News Source Type: news

Genetics of Aspergillosis
Friday, February 16, 2018 - 15:35Slide presentation (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - February 16, 2018 Category: Respiratory Medicine Authors: ROrritt Source Type: news

Why and when aspergillosis first appears in cystic fibrosis patients?
Thursday, February 15, 2018 - 10:48Slide presentation (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - February 15, 2018 Category: Respiratory Medicine Authors: ROrritt Source Type: news

The Human Lung and Aspergillosis: You are what you Breathe in?
Thursday, February 15, 2018 - 10:30Slide presentation (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - February 15, 2018 Category: Respiratory Medicine Authors: ROrritt Source Type: news

Managing breakthrough invasive aspergillosis
Thursday, February 15, 2018 - 10:19Slide presentation (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - February 15, 2018 Category: Respiratory Medicine Authors: ROrritt Source Type: news

Recent Advances in Diagnosis and Treatment of Allergic Aspergillosis
Thursday, February 15, 2018 - 10:18Slide presentation (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - February 15, 2018 Category: Respiratory Medicine Authors: ROrritt Source Type: news

Pulmatrix doses first patient in Ph1 Pulmazole trial
Pulmatrix (NSDQ:PULM) said today that the first patient was treated in a first-in-human study of Pulmazole – an inhaled formulation of the anti-fungal drug, itraconazole. The Lexington, Mass.-based company is evaluating its iSperse formulation of the drug as a treatment for asthma patients who have developed allergic bronchopulmonary aspergillosis. Get the full story at our sister site, Drug Delivery Business News. The post Pulmatrix doses first patient in Ph1 Pulmazole trial appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - February 12, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Pharmaceuticals Respiratory Wall Street Beat Pulmatrix Inc. Source Type: news

8th Advances Against Aspergillosis Conference Round-Up
Mon, 02/05/2018 - 14:02News blog (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - February 5, 2018 Category: Respiratory Medicine Authors: ROrritt Source Type: news

Announcing the Launch of the World Aspergillosis Day Feb 1st
Wed, 01/31/2018 - 16:21News blog (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - January 31, 2018 Category: Respiratory Medicine Authors: GAtherton Source Type: news

Announcing the Launch of World Aspergillosis Day Feb 1st
Wed, 01/31/2018 - 16:21News blog (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - January 31, 2018 Category: Respiratory Medicine Authors: GAtherton Source Type: news

Global health improvement targets announced on World Aspergillosis Day
(Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - January 31, 2018 Category: Respiratory Medicine Authors: GAtherton Source Type: news

Global health improvement targets announced on World Aspergillosis Day Feb. 1st, 2018
(Goodwork) Aspergillosis, lung and sinus disease caused by the fungus Aspergillus, affects around 15 million people and kills over 1 million each year. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 31, 2018 Category: International Medicine & Public Health Source Type: news

Pulmatrix wins EU nod for inhaled dry-powder anti-fungal trial
The UK Medicines and Healthcare Products Regulatory Agency has given Pulmatrix (NSDQ:PULM) the go-ahead to launch its first-in-human study for an inhaled formulation of the anti-fungal drug, itraconazole. The company is evaluating its drug, Pulmazole, as a treatment for allergic bronchopulmonary aspergillosis in patients with asthma. Get the full story at our sister site, Drug Delivery Business News. The post Pulmatrix wins EU nod for inhaled dry-powder anti-fungal trial appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - January 23, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Pharmaceuticals Regulatory/Compliance Respiratory Wall Street Beat Pulmatrix Inc. Source Type: news

Invasive Aspergillosis in Heart Transplant Recipients
Wed, 01/03/2018 - 12:08News blog (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - January 3, 2018 Category: Respiratory Medicine Authors: ROrritt Source Type: news

First CPAnet symposium identifies four key research areas for chronic pulmonary aspergillosis
Thu, 11/16/2017 - 15:40News blog (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - November 16, 2017 Category: Respiratory Medicine Authors: BethBradshaw Source Type: news

ImmunoPET: the future of lung scans in aspergillosis?
Wed, 11/15/2017 - 11:48News blog (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - November 15, 2017 Category: Respiratory Medicine Authors: BethBradshaw Source Type: news

Vitamin D deficiency and aspergillosis
Mon, 11/06/2017 - 17:31News blog (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - November 6, 2017 Category: Respiratory Medicine Authors: BethBradshaw Source Type: news

Hologic to retain CEO MacMillan | Personnel Moves – November 3, 2017
Hologic (NSDQ:HOLX) said this week its current prez and CEO Stephen MacMillan will stay on with the company, resolving rumors that he may depart it to take up the corner office at Zimmer Biomet (NYSE:ZBH). In an SEC filing, the Marlborough, Mass.-based company’s board said it approved a special “performance-based retention equity grant” to MacMillan after he had begun to receive interest from other medical device firms. “Mr. MacMillan has led a dramatic turnaround of Hologic since joining in December 2013. The company’s performance has increased significantly under his...
Source: Mass Device - November 3, 2017 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News ConMed Corp. Hologic Invacare kentimaging Meritech Capital Partners Pulmatrix Inc. Sanofi-Aventis Smith & Nephew Tissue Regenix zimmerbiomet Source Type: news

Did Ötzi the Iceman have aspergillosis?
Did Ötzi the Iceman have aspergillosis?Wed, 10/25/2017 - 12:46News blog (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 25, 2017 Category: Respiratory Medicine Authors: BethBradshaw Source Type: news

Chronic Pulmonary Aspergillosis IV
Monday, October 16, 2017 - 08:36Slide presentation (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 16, 2017 Category: Respiratory Medicine Authors: ROrritt Source Type: news

Chronic Pulmonary Aspergillosis III
Monday, October 16, 2017 - 08:35Slide presentation (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 16, 2017 Category: Respiratory Medicine Authors: ROrritt Source Type: news

Chronic Pulmonary Aspergillosis II
Monday, October 16, 2017 - 08:34Slide presentation (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 16, 2017 Category: Respiratory Medicine Authors: ROrritt Source Type: news

Chronic Pulmonary Aspergillosis I
Monday, October 16, 2017 - 08:32Slide presentation (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 16, 2017 Category: Respiratory Medicine Authors: ROrritt Source Type: news

Efficacy of ambruticin analogs in a murine model of invasive pulmonary aspergillosis
Ambruticins are a family of polyketides. The antifungal activity of an ambruticin,KOSN-2079, was tested in the mouse model of invasive aspergillosis.KOSN-2079 significantly reduced pulmonary fungal burdens and improved survival over that with the vehicle control. These results support the continued development of ambruticins as antifungal agents. (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 11, 2017 Category: Respiratory Medicine Authors: BethBradshaw Source Type: news

Efficacy of the investigational echinocandin ASP9726 in a guinea pig model of invasive pulmonary aspergillosis
ASP9726 is an investigational echinocandin with in vitro activity against Aspergillus species. We evaluated the pharmacokinetics and efficacy of this agent in an established guinea pig model of invasive pulmonary aspergillosis.ASP9726 plasma concentrations were measured in guinea pigs administered either a single dose or multiple doses of this agent at 2.5, 5, and 10 mg/kg of body weight/day by subcutaneous injection. Immunosuppressed guinea pigs were inoculated with A. (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 10, 2017 Category: Respiratory Medicine Authors: BethBradshaw Source Type: news

Researchers help develop new antifungal drug
(University of Liverpool) University researchers, working with F2G Limited (Eccles, Manchester), have developed a new antifungal drug to help in the treatment of life threatening invasive fungal infections such as invasive aspergillosis. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 6, 2017 Category: International Medicine & Public Health Source Type: news

8th Advances Against Aspergillosis: scholarship application deadline
Date: Wednesday, September 20, 2017Year: 2018Location: Lisbon, PortugalContent-type: current_conferences (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - September 20, 2017 Category: Respiratory Medicine Authors: GAtherton Source Type: news

8th Advances Against Aspergillosis: abstract submissions deadline
Date: Wednesday, September 20, 2017Year: 2018Location: Lisbon, Portugal.Content-type: current_conferences (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - September 20, 2017 Category: Respiratory Medicine Authors: GAtherton Source Type: news